NO20052751L - Oftalmisk preparat for behandling av okulaer hypertensjon. - Google Patents

Oftalmisk preparat for behandling av okulaer hypertensjon.

Info

Publication number
NO20052751L
NO20052751L NO20052751A NO20052751A NO20052751L NO 20052751 L NO20052751 L NO 20052751L NO 20052751 A NO20052751 A NO 20052751A NO 20052751 A NO20052751 A NO 20052751A NO 20052751 L NO20052751 L NO 20052751L
Authority
NO
Norway
Prior art keywords
treatment
ocular hypertension
ophthalmic preparation
compounds
eye
Prior art date
Application number
NO20052751A
Other languages
English (en)
Other versions
NO20052751D0 (no
Inventor
James B Doherty
Meng-Hsin Chen
Luping Liu
Swaminathan R Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20052751D0 publication Critical patent/NO20052751D0/no
Publication of NO20052751L publication Critical patent/NO20052751L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Kraftige kaliumkanalblokkerer forbindelser med formel I eller et preparat av dette for behandling av glaukom og andre tilstander som fører til forhøyet intraokulart trykk på øyet hos en pasient. Oppfinnelsen omhandler også anvendelsen av slike forbindelser for å frembringe en neurobeskyttende effekt i pattedyrets øye. spesielt mennesker.
NO20052751A 2002-11-08 2005-06-07 Oftalmisk preparat for behandling av okulaer hypertensjon. NO20052751L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42480802P 2002-11-08 2002-11-08
US50009103P 2003-09-04 2003-09-04
PCT/US2003/035080 WO2004043933A1 (en) 2002-11-08 2003-11-04 Ophthalmic compositions for treating ocular hypertension

Publications (2)

Publication Number Publication Date
NO20052751D0 NO20052751D0 (no) 2005-06-07
NO20052751L true NO20052751L (no) 2005-06-07

Family

ID=32314559

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052751A NO20052751L (no) 2002-11-08 2005-06-07 Oftalmisk preparat for behandling av okulaer hypertensjon.

Country Status (22)

Country Link
US (2) US7196082B2 (no)
EP (1) EP1562909B1 (no)
JP (2) JP4456072B2 (no)
KR (1) KR20050072805A (no)
AR (1) AR041991A1 (no)
AU (2) AU2003287506B8 (no)
BR (1) BR0316040A (no)
CA (1) CA2505086C (no)
CL (1) CL2003002293A1 (no)
DO (1) DOP2003000747A (no)
EC (1) ECSP055781A (no)
HR (1) HRP20050409A2 (no)
IS (1) IS7822A (no)
MA (1) MA27497A1 (no)
MX (1) MXPA05004889A (no)
NO (1) NO20052751L (no)
NZ (1) NZ539593A (no)
PE (1) PE20040692A1 (no)
PL (1) PL377172A1 (no)
RU (1) RU2005117627A (no)
TW (1) TWI250873B (no)
WO (2) WO2004043933A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040028469A (ko) 2002-09-30 2004-04-03 엘지전자 주식회사 1 회 기록 가능한 광디스크의 디펙트 영역 관리방법
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004272546B2 (en) * 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
CN1988903A (zh) * 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
AU2007210073B2 (en) * 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
CA2644716A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2007117465A2 (en) * 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
WO2010051561A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
DK4036094T3 (da) 2014-04-30 2026-03-23 Univ Columbia Erstattede 4-fenylpiperidiner, deres fremstilling og anvendelse
CN104211638A (zh) * 2014-08-13 2014-12-17 李增 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
EP1348437A3 (en) 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3208210B2 (ja) * 1993-03-17 2001-09-10 旭化成株式会社 結晶性芳香族ポリカーボネートプレポリマーの製造方法及び芳香族ポリカーボネートの製造方法
CA2164733A1 (en) 1993-06-08 1994-12-22 Nino Sorgente Methods and compositions for lowering intraocular pressure
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
PL356662A1 (en) 1999-12-22 2004-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
EP1251862B1 (en) 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6956036B1 (en) * 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
KR20030095183A (ko) 2000-03-17 2003-12-18 알콘, 인코퍼레이티드 녹내장 치료용 5-하이드록시 인다졸 유도체
AU4466901A (en) 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
NZ525164A (en) 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie

Also Published As

Publication number Publication date
CL2003002293A1 (es) 2005-01-14
US20040097575A1 (en) 2004-05-20
EP1562909A1 (en) 2005-08-17
AR041991A1 (es) 2005-06-08
JP5061293B2 (ja) 2012-10-31
EP1562909B1 (en) 2012-06-27
BR0316040A (pt) 2005-09-13
CA2505086C (en) 2009-08-25
TW200501949A (en) 2005-01-16
DOP2003000747A (es) 2004-05-31
NO20052751D0 (no) 2005-06-07
KR20050072805A (ko) 2005-07-12
AU2003287506A1 (en) 2004-06-03
NZ539593A (en) 2006-12-22
RU2005117627A (ru) 2006-01-20
WO2004043933A1 (en) 2004-05-27
HRP20050409A2 (en) 2006-02-28
JP2006508190A (ja) 2006-03-09
US7196082B2 (en) 2007-03-27
TWI250873B (en) 2006-03-11
PL377172A1 (pl) 2006-01-23
IS7822A (is) 2005-04-25
JP2010006825A (ja) 2010-01-14
US7547720B2 (en) 2009-06-16
WO2004043932A1 (en) 2004-05-27
AU2003287506B8 (en) 2009-05-28
MA27497A1 (fr) 2005-08-01
MXPA05004889A (es) 2005-07-22
CA2505086A1 (en) 2004-05-27
AU2003286884A1 (en) 2004-06-03
ECSP055781A (es) 2005-09-20
JP4456072B2 (ja) 2010-04-28
AU2003287506B2 (en) 2009-04-23
PE20040692A1 (es) 2004-10-08
US20070129418A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
DK1553953T3 (da) Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom
WO2003047513A3 (en) Method for treating ocular hypertension
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
LU92058I2 (fr) Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
WO2008008330A3 (en) Deuterated ocular solutions for ltk and other surgical eye procedures
DK1239774T3 (da) Apparat til behandling af öjensygdomme
JP2005523928A5 (no)
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
CA2440764A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ATE487514T1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
DK1395263T3 (da) 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
BR0215172A (pt) Derivados de benzodifuranimidazolina e benzofuranimidazolina e seu emprego para o tratamento de glaucoma
ATE511506T1 (de) Thiopen-derivate als wirkstoffe gegen okulare hypotonie
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension
NO20035043D0 (no) Fremgangsmåte for behandling av okular hypertensjon og glaukom
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2002040030A8 (en) Combination therapy for lowering and controlling intraocular pressure